Evidence synthesis and guideline development in genomic medicine: current status and future prospects

Sheri D Schully¹, Tram Kim Lam¹, W David Dotson², Christine Q Chang¹, Naomi Aronson³, Marian L Birkeland⁴, Stephanie Jo Brewster⁵, Stefania Boccia⁶, Adam H Buchanan⁷, Ned Calonge⁸, Kathleen Calzone⁹, Benjamin Djulbegovic¹⁰, Katrina A B Goddard¹¹, Roger D Klein¹², Teri E Klein¹³, Joseph Lau¹⁴, Rochelle Long¹⁵, Gary H Lyman¹⁶, Rebecca L Morgan¹⁷, Christina G S Palmer¹⁸, Mary V Relling¹⁹, Wendy S Rubinstein²⁰, Jesse J Swen²¹, Sharon F Terry²², Marc S Williams²³, Muin J Khoury²⁴

Affiliations

¹ Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
² Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
³ Technology Evaluation Center, Blue Cross Blue Shield Association, Chicago, Illinois, USA.
⁴ National Comprehensive Cancer Network, Fort Washington, Pennsylvania, USA.
⁵ Boston Children's Hospital, Boston, Massachusetts, USA.
⁶ Institute of Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy.
⁷ Duke Cancer Institute, Durham, North Carolina, USA.
⁸ The Colorado Trust, Denver, Colorado, USA.
⁹ Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
¹⁰ 1] University of South Florida, Tampa, Florida, USA [2] H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
¹¹ Kaiser Permanente Northwest, Portland, Oregon, USA.
¹² Department of Molecular Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
¹³ Department of Genetics, Stanford University, Palo Alto,California, USA.
¹⁴ Brown University, Providence, Rhode Island, USA.
¹⁵ National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Maryland, USA.
¹⁶ Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
¹⁷ Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
¹⁸ University of California, Los Angeles, Los Angeles, California, USA.
¹⁹ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
²⁰ National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland, USA.
²¹ Leiden University Medical Center, Leiden, The Netherlands.
²² Genetic Alliance, Washington, D.C., USA.
²³ Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA.
²⁴ 1] Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA [2] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

PMID: 24946156
PMCID: PMC4272332
DOI: 10.1038/gim.2014.69

Evidence synthesis and guideline development in genomic medicine: current status and future prospects

Sheri D Schully et al. Genet Med. 2015 Jan.

. 2015 Jan;17(1):63-7.

doi: 10.1038/gim.2014.69. Epub 2014 Jun 19.

Authors

Affiliations

¹ Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
² Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
³ Technology Evaluation Center, Blue Cross Blue Shield Association, Chicago, Illinois, USA.
⁴ National Comprehensive Cancer Network, Fort Washington, Pennsylvania, USA.
⁵ Boston Children's Hospital, Boston, Massachusetts, USA.
⁶ Institute of Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy.
⁷ Duke Cancer Institute, Durham, North Carolina, USA.
⁸ The Colorado Trust, Denver, Colorado, USA.
⁹ Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
¹⁰ 1] University of South Florida, Tampa, Florida, USA [2] H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
¹¹ Kaiser Permanente Northwest, Portland, Oregon, USA.
¹² Department of Molecular Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
¹³ Department of Genetics, Stanford University, Palo Alto,California, USA.
¹⁴ Brown University, Providence, Rhode Island, USA.
¹⁵ National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Maryland, USA.
¹⁶ Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
¹⁷ Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
¹⁸ University of California, Los Angeles, Los Angeles, California, USA.
¹⁹ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
²⁰ National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland, USA.
²¹ Leiden University Medical Center, Leiden, The Netherlands.
²² Genetic Alliance, Washington, D.C., USA.
²³ Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA.
²⁴ 1] Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA [2] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

PMID: 24946156
PMCID: PMC4272332
DOI: 10.1038/gim.2014.69

Abstract

Purpose: With the accelerated implementation of genomic medicine, health-care providers will depend heavily on professional guidelines and recommendations. Because genomics affects many diseases across the life span, no single professional group covers the entirety of this rapidly developing field.

Methods: To pursue a discussion of the minimal elements needed to develop evidence-based guidelines in genomics, the Centers for Disease Control and Prevention and the National Cancer Institute jointly held a workshop to engage representatives from 35 organizations with interest in genomics (13 of which make recommendations). The workshop explored methods used in evidence synthesis and guideline development and initiated a dialogue to compare these methods and to assess whether they are consistent with the Institute of Medicine report "Clinical Practice Guidelines We Can Trust."

Results: The participating organizations that develop guidelines or recommendations all had policies to manage guideline development and group membership, and processes to address conflicts of interests. However, there was wide variation in the reliance on external reviews, regular updating of recommendations, and use of systematic reviews to assess the strength of scientific evidence.

Conclusion: Ongoing efforts are required to establish criteria for guideline development in genomic medicine as proposed by the Institute of Medicine.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE

The authors declare no conflict of interest.

References

1. Berg JS, Amendola LM, Eng C, et al. Members of the CSER Actionability and Return of Results Working Group. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med. 2013;15:860–867. - PMC - PubMed
1. [Accessed 17 December 2013];GAPP Finder. http://www.hugenavigator.net/GAPPKB/topicStartPage.do.
1. Institute of Medicine. Clinical Practice Guidelines We Can Trust. The National Academies Press; Washington, DC: 2011.
1. Gudgeon JM, McClain MR, Palomaki GE, Williams MS. Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing. Genet Med. 2007;9:473–478. - PubMed
1. Teutsch SM, Bradley LA, Palomaki GE, et al. EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009;11:3–14. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

U01 GM092666/GM/NIGMS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Evidence synthesis and guideline development in genomic medicine: current status and future prospects

Affiliations

Evidence synthesis and guideline development in genomic medicine: current status and future prospects

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources